OpenAI publishes a set of case studies walking through representative questions from its "GeneBench-Pro" benchmark

What was announced

On June 30, 2026, OpenAI published an article titled "Inside Genebench-Pro" that takes a deep dive into representative questions from "GeneBench-Pro," a benchmark for genomics and quantitative biology. It accompanies the introductory article for the benchmark itself, which was announced the same day, and it uses concrete examples to show what the actual questions look like in terms of format and difficulty.

OpenAI News openai.com

The article picks 10 questions as representative examples out of the 129 that make up the benchmark, and for each one it presents the original question text (prompt), the dataset used, and the reference materials together as a set.

Technical points

• The 10 case studies presented are all excerpts from the 129 questions that make up GeneBench-Pro itself
• Each case study consists of a three-part set: the question prompt, a synthetic dataset, and the reference material used as the grading criterion
• As one representative example, the article presents a question based on a registry of solid-tumor cases that are candidates for a trial of an inhibitor targeting TXR1 (a fictional molecular target)
• In this question, you are asked to first identify the subgroup in which TXR1's target pathway is activated by structural variants (SVs), drawing on evidence from long-read sequencing, gene expression, tumor quality, and pharmacogenomics. Then you have to estimate the difference in clinical benefit at 16 weeks between the TXR1 inhibitor and non-TXR1-based systemic therapy, as well as the risk of treatment-limiting toxicity or discontinuation at 8 weeks
• All of these questions are synthetically generated from known causal structures, and they are not real patient data

My take and how it can be used

Publishing actual example questions, rather than just abstract scores, is a helpful stance for letting third parties verify the validity of a benchmark. The TXR1 case in particular clearly requires integrating multiple kinds of evidence, such as genes, imaging, and pharmacogenomics, to perform reasoning close to real clinical decision-making, so you can see it's designed so it can't be solved by simple knowledge recall. Even though the data is synthetic, as a task set with complexity close to real practice, I'm looking forward to other AI vendors trying to replicate it as well.